Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, August 12, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, includ ...

Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK, July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter. "Our com ...

NEW YORK, July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com. "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experi ...

Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK, June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part ...

Exhibit 99.1 Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results Quarterly EsoGuardtest volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering MolDX pre-submission meeting scheduled for July 17, 2024 Conference call and webcast to be held today, May 13 at 8:30 AM EDT NEW YORK, May 13, 2024 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diag ...

财务数据和关键指标变化 - 第一季度收入略超过1百万美元,与上一季度持平,同比增长124% [9] - 第一季度检测量为2,420例,环比增长约10%,同比增长31% [9] - 毛利率约90% [16] - 非GAAP净亏损为940万美元,环比改善50万美元,同比改善40万美元 [51] 各条业务线数据和关键指标变化 - 公司主要通过自有门诊中心、与医生诊所合作、移动检测中心等多种渠道开展业务 [17] - 第一季度举办了32场高量健康检查活动(CheckYourFoodTube),并建立了中央远程医疗系统 [20] - 正在积极推进与福利经纪人、第三方管理人和自保险实体的直接合同,为患者提供EsoGuard作为保险承保福利 [21][22] 各个市场数据和关键指标变化 - 公司正在积极执行市场准入策略,包括与区域医疗保险公司争取医疗政策承保,在有生物标志物立法的州获得承保,以及与全国性保险公司开展试点项目 [25][26][27] - 在出网支付方面,约半数索赔获得支付,平均支付约1,800美元,与Medicare支付水平接近 [23][56] - 公司正在采取多项措施改善收款流程,包括事前授权、上诉、医生倡导等 [23][24] 公司战略和发展方向及行业竞争 - 公司专注于预癌早期检测,目标是通过早期发现预防食管癌死亡 [12] - EsoGuard检测在预癌检测敏感性和特异性方面表现优于其他同类检测,如结直肠癌筛查的Cologuard和液体活检Guardant [13][14][15] - 公司正在积极推进与Medicare和私人保险公司的医疗政策谈判,以获得承保 [25][26][27] - 公司收购并停止供应了一种竞争性的食管细胞采集设备EsophaCap,该设备存在严重安全隐患 [99][100][101][102][103][106] 管理层对经营环境和未来前景的评论 - 管理层对公司的商业执行和近期里程碑感到兴奋和乐观 [7][125] - 公司将继续关注市场准入、直接合同等工作,并密切关注Medicare和私人保险公司的承保决定 [45][58][116] - 管理层认为公司的技术和临床数据优势明显,未来有望实现大规模商业化 [88][89][110][111] 问答环节重要的提问和回答 问题1 **Mike Matson 提问** 询问公司与MolDX的预提交会议的具体情况和可能的结果 [60] **Lishan Aklog 回答** 解释了预提交会议的目的是与MolDX医疗总监讨论公司的全面证据数据,为后续正式提交技术评估做准备 [61][62][63] 问题2 **Anthony Vendetti 提问** 询问公司与主要保险公司的报销情况及未来覆盖可能性 [75] **Lishan Aklog 回答** 解释目前公司主要集中于区域性保险公司和有生物标志物立法的州,对大型保险公司的谈判策略是等待Medicare和行业指南的覆盖 [76][77][78] 问题3 **Kyle Mikson 提问** 询问公司此前收购CapNostics的背景,以及对竞争格局的影响 [97] **Lishan Aklog 回答** 解释了收购CapNostics的初衷,以及最终决定停止供应其产品EsophaCap的原因,认为这有利于公司的技术优势 [98][99][100][101][102][103][106][107]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-40901 LUCID DIAGNOSTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-5488042 (State or Oth ...

EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection NEW YORK, May 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophage ...

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAV ...

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a busine ...